Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
- 1 January 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Cardiology
- Vol. 24 (1), 50-55
- https://doi.org/10.1097/hco.0b013e32831bc336
Abstract
Rhythm control remains of therapeutic value for many atrial fibrillation patients despite no evidence of survival benefit. This lack of benefit may relate to side effects of conventional antiarrhythmic drugs. The introduction of novel agents was a logical consequence. Novel antiarrhythmics are currently being evaluated in preclinical or clinical studies. Among recently developed drugs, some affect one or more atrial targets, including IKur, IKACh, INa or ISAC, allowing them to act selectively on atria over ventricles. Some drugs that exhibit atrial selectivity have not been successful in preliminary studies. Block of a single atrial-specific target may be insufficient for atrial fibrillation termination and prevention, and multichannel-blocking properties may be a useful alternate approach. Drugs such as vernakalant or ranolazine inhibit multiple channels but display effective and atrial-selective actions. Furthermore, dronedarone, a prototypic multichannel blocker with additional effects on ventricular myocardium, has proven well tolerated and effective in the treatment of atrial fibrillation and may even reduce cardiovascular mortality. Efforts to develop atrial-selective antiarrhythmics are bearing fruit, but such compounds will need to exhibit equal or superior safety and efficacy compared with multichannel blockers such as dronedarone for atrial fibrillation suppression in order to prove their worth. It is still too early to tell whether atrial selectiveness is just hype or truly a hope for antiarrhythmic drug treatment of atrial fibrillation.Keywords
This publication has 48 references indexed in Scilit:
- Pathology‐specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillationBritish Journal of Pharmacology, 2008
- Can inhibition of IKur promote atrial fibrillation?Heart Rhythm, 2008
- Atrial-Selective Sodium Channel Block as a Strategy for Suppression of Atrial FibrillationAnnals of the New York Academy of Sciences, 2008
- Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial FibrillationCirculation, 2007
- Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or FlutterNew England Journal of Medicine, 2007
- The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in HumansJournal of Cardiovascular Pharmacology, 2007
- Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agentExpert Opinion on Investigational Drugs, 2007
- Anti-arrhythmic Effects of I Na, I Kr, and Combined I Kr–I CaL Blockade in an Experimental Model of Acute Stretch-Related Atrial FibrillationCardiovascular Drugs and Therapy, 2007
- Ranolazine Improves Abnormal Repolarization and Contraction in Left Ventricular Myocytes of Dogs with Heart Failure by Inhibiting Late Sodium CurrentJournal of Cardiovascular Electrophysiology, 2006
- The Mechanism of Atrial Antiarrhythmic Action of RSD1235Journal of Cardiovascular Electrophysiology, 2005